- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Paclitaxel, Carboplatin, Bevacizumab, IMNN-001
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 8
- States / cities
- Orlando, Florida • Minneapolis, Minnesota • St Louis, Missouri + 5 more
- Conditions
- HIV Infections
- Interventions
- p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
- Biological · Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- San Francisco, California • Decatur, Georgia • Cleveland, Ohio
- Conditions
- HIV Infection
- Interventions
- PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
- Biological · Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- HIV-1-infection
- Interventions
- PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
- Biological · Device
- Lead sponsor
- Steven Deeks
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- HIV Infections
- Interventions
- PENNVAX-B, IL-12 DNA plasmids
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- HIV Infections
- Interventions
- PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more
- Conditions
- HIV, Therapeutic Vaccine
- Interventions
- rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2008
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
- Conditions
- HCC
- Interventions
- GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012
- Biological · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more